29 stories found
International and U.S. courts have issued separate patent infringement rulings, ordering Samsung to pay Swatch $11.6 million for copying smartwatch applications and directing Guardant Health to pay $245 million for infringing cancer diagnostic patents. The decisions highlight ongoing legal battles over intellectual property in technology and healthcare.
Guardant Health (GH) has seen a significant surge in its stock value, driven by recent FDA approval for its products and growing momentum in the cancer screening market. This development positions the company for potential growth in the healthcare sector.
Guardant Health (GH) announced strong financial results for its second quarter, exceeding expectations.
Guardant Health has received a new 'Outperform' rating from RBC, citing potential catalysts and strong growth prospects for the company.
Several companies, including EverCommerce, Inogen, AerSale, Treace, CarGurus, and Guardant Health, have either released or reaffirmed their revenue outlooks and financial guidance for 2026. Some also provided specific projections for Q2 2026, detailing growth strategies and targets.
Several companies, including ATN International, EVERTEC, Montrose Environmental, Phibro Animal, UGI, and TKO, have released their latest quarterly financial results. While some companies reported earnings that beat analyst expectations, others missed revenue or EPS forecasts.
Guardant Health and Verana Health have announced a new partnership.
Guardant Health (GH) announced financial results that surpassed expectations, leading to gains for the company.
Guardant Health anticipates 27-30% revenue growth for 2026, fueled by the expansion of its Shield and oncology portfolio.
A court has ruled that Guardant Health must pay $245 million to resolve a patent dispute over DNA sequencing technology, marking a significant legal victory for the opposing party.
Guardant Health (GH) has reported a 48% growth, attributed to the increasing momentum and adoption of its cancer testing products.
Shares of Guardant Health have seen a significant surge following news related to its colon cancer blood test, indicating positive market reaction to the development.
Dynatrace announced its FY2026 ARR surpassed $2 billion driven by strong Q4 revenue growth, while Guardant Health reported a 48% jump in Q1 revenue to $301.7 million due to robust screening growth. Both companies showcased significant financial performance.
Guardant Health has released the transcript of its first-quarter 2026 earnings call, detailing the company's financial performance and outlook.
An analysis explores whether Guardant Health (GH) possesses a long runway for sustained growth in the market. The article delves into factors that could contribute to its future expansion.
Piper Sandler has reiterated its bullish stance on Guardant Health, citing the company's 2026 screening story as a key factor supporting its positive outlook.
The Korea Medical Institute said Tuesday it has signed a memorandum of understanding with US-based Guardant Health to collaborate on liquid biopsy-based precision cancer screening.
Guardant Health has acquired MetaSight, an Israeli health technology company, in a deal valued at up to $150 million.
Guardant Health (GH) has been highlighted as a good healthcare holding, suggesting positive prospects for the company within the sector.
Guardant Health has announced its intention to appeal a recent ruling by a Delaware court concerning a patent case. The company seeks to challenge the court's decision.
Major tech companies like Amazon and Microsoft reported strong earnings driven by significant investments in AI, while Apple warned of future supply constraints impacting Mac, iPhone, and iPad sales, leading to a projected slowdown in September-quarter growth.
Guardant Health's stock has risen following UnitedHealth's decision to provide coverage for its Shield test, a move expected to boost the company's market position.
Evercore ISI has reiterated an "In Line" rating for Guardant Health, Inc. (GH).
Guardant Health has announced the resignation of its Chief Marketing Officer.
Analysts are presenting conflicting views on the prospects of several healthcare companies, including CareDx (CDNA), Biogen (BIIB), and Guardant Health (GH).
Guardant Health, Inc. has announced the acquisition of MetaSight Diagnostics, a move aimed at strengthening its health technology portfolio and expanding its capabilities in the diagnostics sector.
Key highlights from Guardant Health's fourth-quarter earnings call have been released.